excluded. The study included women with fertility issues aged 20-50 years submitted to IVF. A total of 733 patients were included. The patients were divided by age into three groups (≤35 years old; 36-39 years old; ≥40 years old).Results: The mean AMH concentration ranged from 2.65 to 1.35 ng/mL and was significantly different between the groups. The mean total number of retrieved oocytes ranged from 9.5 to 5.42 and was significantly different between the groups. The mean number of mature oocytes ranged from 7.14 to 4.58. There was no significant difference in the number of mature oocytes between patients aged 36-39 years and ≥40 years. Negative correlations were observed between patient age and total number of retrieved oocytes (-0.3354) and number of mature oocytes (-0.2839). AMH was negatively correlated with age (-0.3257), although positive correlations with total number of oocytes (0.6702) and number of mature oocytes (0.5770) were observed.Conclusions: This is the largest study performed with Brazilian patients to correlate AMH levels, age, number of oocytes, and number of mature oocytes from controlled ovarian stimulation cycles. Our data showed that as age increases, AMH levels, number of retrieved oocytes, and number of mature oocytes decrease significantly. However, no significant difference in number of mature oocytes was observed when patients aged 36-39 and ≥40 years were compared. In addition, a positive correlation was found between serum AMH levels and total number of retrieved and mature oocytes from stimulated cycles.

BACKGROUNDLeprosy is a chronic granulomatous infectious disease caused by Mycobacterium leprae, which mainly affects the skin and peripheral nerves. Between 2016 and 2020, 155,359 new cases of this disease were diagnosed in Brazil. In addition to neuropathic pain, leprosy presents itself uncommonly in rheumatology practice in different ways, from arthritis to polyneuritis, and rheumatologists should be aware of this condition. Leprosy neuropathy is a situation which proper management must be broadly addressed, as it brings many harms to patients. CASES REPORT1) OFO, 40 years old, with leprosy for 4 years, type II multibacillary reaction, after 1 year it started with burning in the upper limbs accompanied by erythema nodosum and neuritis with bilateral ulnar nerve thickening. In addition to treating the underlying disease, he was treated for neuropathic pain with gabapentin 900 mg/day, codeine 120 mg/day, and amitriptyline 25 mg/day. There was a reduction in visual pain scale (VPS) from 10 (first visit) to 4 (current).2) MINK, 42 years old, with leprosy for 5 years, type I multibacillary reaction, started with paresthesias and burning in the lower limbs, with reduced muscle strength. Electroneuromyography showed axonal and sensory-motor demyelinating polyneuropathy of sensory predominance. She performed a sural nerve biopsy with a result of inflammatory neuritis and axonal demyelination. Treated with gabapentin 1,800 mg/day, codeine 120 mg/day and amitriptyline 25 mg/day. Initial VPS reduction from 10 to 4.3) LB, 40 years old, with leprosy for 8 years, type I multibacillary reaction, with burning and shock with paresthesia in the limbs. In use of carbamazepine 1,600 mg/day, methadone 40 mg/day and paracetamol 2,000 mg/day. Initial VPS reduction from 10 to 2. 4) SMG, 48 years old, with leprosy for 3 years. Multibacillary type I reaction, with allodynia with burning in the upper limbs and reduced muscle strength. Managed with duloxetine 60 mg/day, tramadol 200 mg/day and pregabalin 150 mg/day. VPS reduction from 9 to 3. CONCLUSIONLeprosy neuropathy is an important condition, given the varied manifestations and the impairment in the patient's quality of life. Knowledge about the proper management of this condition is of paramount importance, and tricyclic antidepressants represent a good choice, with amitriptyline being the most used. Carbamazepine, gabapentin and drugs with central analgesic potential can also be associated. Acting on pain is a physician's duty and a patient's right to improve quality of life and disease outcome.

No abstract